GLPG - Galapagos NV Stock Trading

Galapagos NV(NASDAQ: GLPG) stock trading, description, contact, officers and directors.

About Galapagos NV

Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti infectives. Galapagos approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target to drug discovery products and services to pharmaceutical and biotech companies.

Stock Information

Trending Stock

22.47%Change Percent:

Galapagos NV Company Name:

GLPG Stock Symbol:

NASDAQ Market:

Galapagos NV Website:

GLPG - Galapagos NV Stock Trading

GLPG GLPG Quote GLPG Short GLPG News GLPG Articles GLPG Message Board

Get GLPG Alerts

News, Short Squeeze, Breakout and More Instantly...

GLPG - Why Galapagos Trounced the Market Today

A changing of the guard is coming at biotech Galapagos (NASDAQ: GLPG) , with the announcement of a new CEO. Investors were quite happy to hear this, and consequently the stock ended the day more than 22% higher. Belgium-based Galapagos announced Wednesday afternoon that it has t...
GLPG - Galapagos appoints Paul Stoffels as Chief Executive Officer

Succeeds current Chief Executive Officer and co-founder Onno van de Stolpe, following planned retirement Recognized as inspirational industry leader with exceptional R&D as well as global executive experience, and a strong focus on bringing innovative medicines t...
GLPG - JYSELECA®? (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN

Mechelen, Belgium ; 18 January 202 2 ; 22 .01 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Jyseleca &#x...